Does insurance cover Wegovy?

If you’ve been exploring GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss or diabetes management, you’ve likely wondered: Will my insurance actually cover this? These highly effective medications carry steep price tags—often over $1,000 per month without coverage—making insurance approval crucial for most patients.

The short answer? It depends—on your insurance type, your diagnosis, where you live, and whether you can navigate the prior authorization maze. This guide breaks down exactly what you need to know about GLP-1 insurance coverage in 2025, including recent policy changes, state-by-state Medicaid differences, and what to do if you’re denied.

Understanding GLP-1 Medications: Not All Prescriptions Are Created Equal

Before diving into insurance, it’s important to understand that these medications have different FDA approvals:

• Wegovy (semaglutide): FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition
• Ozempic (semaglutide): FDA-approved for Type 2 diabetes management, not weight loss (though it contains the same active ingredient as Wegovy)
• Mounjaro (tirzepatide): FDA-approved for Type 2 diabetes, not obesity (Zepbound is the weight-loss version)

This distinction matters enormously for insurance. Insurers generally cover drugs only for their FDA-approved uses—meaning Ozempic will be covered for diabetes but typically denied for weight loss, even though many doctors prescribe it off-label for that purpose.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: What to Expect

Coverage for Diabetes Medications (Ozempic & Mounjaro)

If you have Type 2 diabetes, you’re in a better position. Most commercial insurance plans cover Ozempic and Mounjaro as diabetes treatments, though not without some hurdles:

Prior Authorization Requirements: Nearly all plans require documentation that you have Type 2 diabetes and may need proof that you’ve tried first-line treatments like metformin. Some insurers require trying a less expensive GLP-1 medication before approving Mounjaro, given its higher cost.

Typical Tier Placement: These medications usually fall into Tier 3 (non-preferred brand) or Tier 4 (specialty), meaning higher copays—often $50-$150 per month with insurance, or 20-40% coinsurance on some plans.

Important Note: Even with diabetes, insurers will deny coverage if they suspect the primary goal is weight loss. The prescription must clearly document diabetes management as the indication.

Coverage for Weight Loss (Wegovy)

This is where things get complicated. Many employer-sponsored health plans explicitly exclude anti-obesity medications, viewing them as optional benefits due to cost concerns. Among plans that do cover Wegovy, expect:

Strict Prior Authorization Criteria:

• BMI ≥30 (or ≥27 with at least one weight-related comorbidity like hypertension, sleep apnea, or prediabetes)
• Documentation of at least 6 months of supervised diet and lifestyle modification attempts
• Age restrictions (typically 18+, though some plans cover pediatric use)
• Periodic re-evaluation requirements (must demonstrate ≥5% weight loss to continue coverage)

Step Therapy: Some insurers require trying older, cheaper weight-loss medications (like phentermine or orlistat) first, though this varies by plan.

Coverage Duration: Initial approvals often last just 3-6 months. Continued coverage requires proving the medication is working through documented weight loss and adherence to lifestyle changes.

According to recent KFF data, employer coverage of GLP-1 weight-loss drugs remains limited, with many large companies opting out due to budget impacts. Even when covered, the copay can be substantial—$100-$300 per month is common on Tier 3-4 formularies.

Medicare Coverage: The Legal Exclusion

Here’s where federal law creates a major barrier: Medicare Part D cannot cover drugs used solely for weight loss. This exclusion, written into the Social Security Act, means traditional Medicare beneficiaries generally cannot get Wegovy covered, period.

The One Exception: In March 2024, Medicare announced it would cover Wegovy for patients with established cardiovascular disease and obesity, based on the FLOW trial showing it reduces major cardiac events. This narrow exception requires documented heart disease plus obesity—not weight loss alone.

For Diabetes: Medicare Part D does cover Ozempic and Mounjaro for Type 2 diabetes management, treating them like other diabetes medications with typical formulary placement and prior authorization to confirm diagnosis.

Medicare Advantage Plans: Some MA plans began offering limited GLP-1 obesity coverage in 2025 through supplemental benefits, but this varies dramatically by plan. Check your specific policy’s formulary.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage of weight-loss GLP-1s varies wildly by state because federal law makes anti-obesity drugs an optional Medicaid benefit. States can choose to cover them—or not—and many are now cutting coverage due to budget pressure.

States With Coverage (Subject to PA)

Pennsylvania: As of mid-2024, PA Medicaid covered Wegovy with strict criteria (BMI ≥30 or ≥27 + comorbidity, documented lifestyle attempts, etc.). However, Pennsylvania announced it will discontinue this coverage in January 2026 due to unsustainable costs.

New York: NYRx formulary includes Wegovy under ‘Anti-Obesity Agents’ with prior authorization. Criteria include BMI thresholds, age ≥18, and proof of lifestyle intervention. Quantity limits apply (typically 4 pens per 28 days).

States Without Coverage

Texas: Texas Medicaid explicitly excludes all obesity medications for adults 21 and older. Wegovy, Saxenda, and similar drugs are non-formulary. Children under 21 may request exceptions through EPSDT (Early and Periodic Screening, Diagnostic, and Treatment), but adult coverage is prohibited.

Florida: Does not cover weight-loss drugs under Medicaid, exercising the federal exclusion option. Only diabetes-indicated GLP-1s (Ozempic for T2D) are covered.

Illinois: No Medicaid coverage for anti-obesity medications as of 2025. While Illinois expanded coverage for state employees in 2023, this did not extend to Medicaid enrollees.

Recent Cuts

California: Medi-Cal covered Wegovy, Saxenda, and Zepbound with prior authorization through 2025, but all three will be removed from the formulary on January 1, 2026. This reflects California’s budget challenges, with GLP-1 spending reportedly consuming significant pharmacy resources. Pediatric patients may still access these drugs via EPSDT exceptions.

According to a Forbes analysis, only about 13 states covered GLP-1 weight-loss medications as of late 2024, and that number is shrinking. States that do cover invariably require BMI documentation, proof of 6+ months of diet/exercise programs, and ongoing monitoring.

Common Reasons for Denial (and How to Appeal)

Even when your insurance theoretically covers these medications, denials are common. Understanding why can help you appeal successfully.

Top Denial Reasons

1. Insufficient Medical Necessity: Your documented BMI doesn’t meet the threshold, or comorbidities aren’t adequately documented in your medical record.

2. Incomplete Lifestyle Documentation: Insurers often require detailed notes proving you attempted supervised diet and exercise for 6 months. A simple ‘patient tried to lose weight’ won’t suffice—they want documented programs, weigh-ins, and nutritional counseling records.

3. Off-Label Use: Requesting Ozempic for weight loss when you don’t have diabetes will almost always result in denial. The prescription must match FDA-approved indications.

4. Plan Exclusion: If your employer’s health plan categorically excludes ‘weight control drugs,’ no amount of medical justification will overcome that policy barrier (though sometimes exceptions exist for specific medical conditions like severe obesity-related sleep apnea).

5. Step Therapy Failure: You haven’t tried and failed less expensive weight-loss treatments first, or (for diabetes) you haven’t tried metformin or another first-line medication.

How to Appeal Effectively

If denied, don’t give up. Many initial denials are overturned on appeal when proper documentation is provided:

Gather Comprehensive Documentation:

• Complete medical records showing BMI measurements over time
• Documentation of all weight-related comorbidities (hypertension, prediabetes, sleep apnea, etc.)
• Detailed records of supervised diet/exercise programs, including dates, providers, and weight logs
• Letter of medical necessity from your provider explaining why this specific medication is essential

Submit a Formal Appeal: Most plans allow a two-level internal appeal process. Your first appeal should address exactly why you meet the coverage criteria, point by point.

Timeline Expectations: Initial prior authorizations typically take 5-7 business days. Appeals can take 2-3 weeks. Request an expedited review if there’s urgent medical need.

Physician Peer-to-Peer Review: Sometimes your doctor can request a phone consultation with the insurance company’s medical director to explain the clinical rationale. This often helps when denials are based on misunderstanding rather than policy.

External Review: If internal appeals fail, most states allow external review by an independent medical expert. Success rates vary, but cases where you clearly meet stated criteria have good odds.

Studies suggest that persistent, well-documented appeals do succeed in a meaningful percentage of cases—particularly for patients with BMI ≥35 and multiple comorbidities where medical necessity is clear.

Telehealth Visits and Insurance

Good news: Insurance coverage for telehealth weight management is generally strong. Since the pandemic, most major insurers and Medicare expanded virtual care coverage, and over 40 states have enacted telehealth parity laws requiring insurers to cover telemedicine equivalently to in-person care.

What’s Typically Covered

• Virtual consultations with doctors, nurse practitioners, or registered dietitians for weight management
• Nutritional counseling for obesity (an ACA-mandated preventive service, often available at no cost)
• Follow-up visits for medication management and monitoring

Potential Limitations

Network Requirements: You typically need to see an in-network provider. Many telehealth platforms, including Klarity Health, work with your insurance or offer transparent self-pay options if you prefer not to use insurance.

Visit Type: Some plans require live video rather than phone-only or asynchronous messaging for full coverage.

Prescription Coverage: Even if your telehealth visit is covered, the prescription itself must still meet formulary requirements. A covered telehealth visit doesn’t guarantee covered medication.

Klarity Health offers flexible options—whether you’re using insurance or paying out-of-pocket, you can access qualified providers who understand the nuances of GLP-1 prescribing and prior authorization requirements. With transparent pricing and availability across all 50 states, Klarity makes it easier to navigate weight loss treatment, regardless of insurance hurdles.

Self-Pay Options: What If Insurance Won’t Cover?

If your insurance denies coverage or doesn’t include these medications, recent manufacturer price reductions and third-party programs have made self-pay more accessible.

GoodRx Partnership Program (New in Late 2025)

GoodRx partnered with Novo Nordisk to offer dramatically reduced cash prices:

• Wegovy or Ozempic: $199/month for the first two months, then $349/month ongoing (lower doses)
• This represents a 65-70% discount from the ~$1,000-$1,350 list price

Manufacturer Savings Programs

Novo Nordisk:

• Savings Card (for insured patients): Can reduce copays to as little as $0-$25 per month (covers up to $225 of your cost). Requires commercial insurance; cannot be used with Medicare or Medicaid.
• Wegovy Access Program: Self-pay patients can get Wegovy for $349/month at participating pharmacies (down from $499 previously)

Eli Lilly:

• Mounjaro Savings Card: $25/month for commercially insured patients with Type 2 diabetes (covers up to ~$500)
• Zepbound Vials: Lilly introduced lower-cost single-dose vials at $299-$449/month (depending on dose) through LillyDirect, down from previous pricing

Patient Assistance Programs

Both Novo Nordisk and Eli Lilly offer free medication to qualifying low-income, uninsured patients (typically those earning <400% of federal poverty level). Applications take several weeks but can provide a year’s supply at no cost if you meet criteria.

Important Cautions

Compounded Medications: Some telehealth companies and ‘wellness’ clinics offer compounded semaglutide or tirzepatide at lower prices ($200-$400/month). These are not FDA-approved products and may pose quality and safety risks. The FDA has issued warnings about compounded GLP-1s due to contamination and dosing inconsistencies.

Generic Alternatives: There are currently no true generics for these medications. Patents extend into the 2030s for semaglutide and tirzepatide. Older weight-loss medications (phentermine, orlistat) are much cheaper ($30-$100/month) but work through different mechanisms with lower efficacy.

State-by-State Medicaid Quick Reference

Making the Most of Your Coverage Options

Navigating GLP-1 insurance coverage requires patience and persistence, but understanding the system dramatically improves your odds of success. Here’s your action plan:

If You Have Commercial Insurance

1. Check your formulary: Log into your insurance portal and search for Wegovy, Ozempic, or Mounjaro. Look for tier placement and any coverage notes.

2. Review prior authorization requirements: Your plan should list specific criteria. Common requirements include BMI documentation, comorbidity proof, and lifestyle intervention records.

3. Work with your provider: Make sure your doctor thoroughly documents your weight history, attempted interventions, and medical necessity in your chart. This documentation is crucial for PA approval.

4. Consider timing: Submit PAs early in the process and allow 2-3 weeks for processing. Follow up if you don’t hear back within a week.

5. Be prepared to appeal: If initially denied, request the specific reason and address each criterion in your appeal with supporting documentation.

If You Have Medicare

1. Understand the limitation: Traditional Part D won’t cover weight-loss use, but will cover diabetes indications.

2. Check for exceptions: If you have established cardiovascular disease plus obesity, Wegovy may be covered under the cardiac risk reduction indication.

3. Review Medicare Advantage: Some MA plans offer supplemental obesity benefits. Compare plans during open enrollment if this matters to you.

4. Explore Medigap + cash: Some beneficiaries use Medicare for most care but pay cash or use manufacturer programs for weight-loss medications.

If You Have Medicaid

1. Verify your state’s policy: Check your state Medicaid formulary (often called PDL – Preferred Drug List) for current coverage status.

2. Act before policy changes: If your state covers these drugs but announcements suggest changes (like California and Pennsylvania), work with your provider to get approved before cutoff dates.

3. Consider EPSDT if under 21: Pediatric Medicaid enrollees often have broader coverage through EPSDT provisions.

4. Document everything: Medicaid PAs typically require extensive documentation. Keep detailed records of all weight-loss attempts and medical visits.

Beyond Insurance: The Role of Comprehensive Care

While insurance coverage is important, successful weight management extends far beyond medication access. The most effective outcomes occur when GLP-1 medications are combined with:

• Nutritional counseling and sustainable eating pattern changes
• Regular physical activity tailored to your abilities and health status
• Behavioral health support addressing emotional eating, stress management, and habit change
• Ongoing medical monitoring for side effects and comorbidity improvement

Platforms like Klarity Health streamline this comprehensive approach. Rather than navigating multiple providers and systems, you can access prescribers, nutritional guidance, and follow-up care through one platform—whether you’re using insurance or self-pay. With providers available seven days a week and appointments often available within 24 hours, Klarity removes common barriers to accessing weight-loss treatment.

Klarity’s transparent pricing model is particularly valuable for those whose insurance won’t cover GLP-1s or who face months-long waits for in-network endocrinologists. You’ll know upfront what you’re paying for both the visit and, if appropriate for you, medication management guidance.

The Bottom Line on GLP-1 Insurance Coverage

Insurance coverage for GLP-1 medications in 2025 is inconsistent and complex, but not impossible to navigate:

• Diabetes use (Ozempic, Mounjaro) is generally covered by commercial insurance and Medicare Part D, though prior authorization is common
• Weight-loss use (Wegovy) faces much stricter limitations: many commercial plans exclude it, Medicare doesn’t cover it (with rare exceptions), and Medicaid coverage is shrinking
• State Medicaid programs are actively reducing or eliminating obesity medication coverage due to cost, with California and Pennsylvania ending coverage in January 2026
• Telehealth coverage is strong for weight management visits, making virtual care a viable option
• Self-pay options have improved significantly with manufacturer price reductions and GoodRx partnerships dropping costs to $199-$349/month in many cases

If you’re seeking GLP-1 treatment:

• Start by thoroughly understanding your insurance policy and formulary
• Work closely with your provider to build a strong medical necessity case
• Be prepared for prior authorization requirements and potential appeals
• Don’t hesitate to explore manufacturer savings programs and patient assistance if insurance won’t cover
• Consider comprehensive virtual care platforms that accept both insurance and cash pay for flexibility

With healthcare costs rising and obesity rates climbing, access to effective treatments shouldn’t require an insurance law degree. Whether you’re managing diabetes, addressing obesity, or both, understanding your coverage options—and alternatives when insurance falls short—empowers you to make informed decisions about your health.

Frequently Asked Questions

Q: Can I use my insurance for a telehealth visit to discuss GLP-1 medications?

A: Yes, most insurance plans now cover telehealth visits for weight management and diabetes care equivalently to in-person visits. Check that your provider is in-network, and confirm your plan covers virtual consultations. Many platforms, including Klarity Health, work with insurance or offer transparent self-pay pricing.

Q: What happens if my insurance approves Wegovy but then I stop losing weight?

A: Most plans require periodic re-evaluation (every 3-6 months). To maintain coverage, you typically must demonstrate continued weight loss (≥5% initial loss, then maintenance) and adherence to lifestyle modifications. If you plateau without meeting goals, coverage may be discontinued.

Q: Will my insurance cover both the medication AND nutritional counseling?

A: Often yes—nutritional counseling for obesity is an ACA-mandated preventive service that many plans must cover without copay. The medication itself has separate coverage rules (prior authorization, formulary tier, etc.). Check your specific plan benefits for preventive services.

Q: If Medicare doesn’t cover weight-loss drugs, what are my options as a senior?

A: Medicare beneficiaries can: (1) use manufacturer savings programs or patient assistance (income-based), (2) pay cash using GoodRx discounts (~$349/month for Wegovy), (3) check if a Medicare Advantage plan offers supplemental obesity benefits, or (4) qualify for cardiac risk coverage if you have established heart disease plus obesity.

Q: My employer plan excludes ‘weight control drugs’—can my doctor appeal based on medical necessity?

A: Possibly, but challenging. When a plan categorically excludes a class of drugs, appeals rarely succeed unless you can argue an alternative covered indication (like using Wegovy for CV risk reduction in someone with obesity-related heart disease). Review your Summary Plan Description for any exception processes. Some employers make exceptions for severe cases.

Q: Are compounded semaglutide products from online clinics safe and covered by insurance?

A: Compounded versions are not FDA-approved and carry quality risks (contamination, incorrect dosing). Insurance typically doesn’t cover compounded drugs when an FDA-approved version exists. The FDA has issued warnings about these products. If cost is a barrier, explore manufacturer assistance or GoodRx programs for the FDA-approved medications instead.

Ready to Start Your Weight-Loss Journey?

Navigating insurance shouldn’t stand between you and better health. Whether your insurance covers GLP-1 medications or you’re considering self-pay options, Klarity Health offers accessible, transparent care:

✓ Board-certified providers experienced in obesity medicine and metabolic health
✓ Appointments available 7 days a week, often within 24 hours
✓ Flexible options: accepts insurance or offers clear cash-pay pricing
✓ Comprehensive support: medication management, lifestyle guidance, and ongoing monitoring

Don’t spend months waiting for specialists or fighting insurance denials alone. Get started with a provider who understands both the medical and insurance complexities of GLP-1 treatment.

Schedule your consultation with Klarity Health today and take the first step toward sustainable weight loss—regardless of insurance hurdles.

📅 RESEARCH CURRENCY STATEMENT (Verified as of 2025-12-17)

Verified coverage status and pricing are accurate as of December 17, 2025. Always check your own insurance formulary for the latest details, as policies can change with new plan years.

Top 5 Citations

1. California DHCS Medi-Cal Policy Update – Official announcement regarding discontinuation of GLP-1 weight-loss drug coverage effective January 1, 2026 (www.cmadocs.org)

2. KFF Issue Brief: Medicaid Coverage of GLP-1s – Comprehensive analysis showing only 13 states cover obesity medications, with detailed survey data on state policies and coverage criteria (November 2024) (www.kff.org)

3. GoodRx Partnership Announcement – Official press release detailing new $199 introductory pricing and $349 ongoing pricing for Wegovy and Ozempic through pharmacy network (November 17, 2025) (www.businesswire.com)

4. Fierce Pharma: Manufacturer Price Reductions – Industry reporting on Novo Nordisk and Eli Lilly reducing self-pay prices for GLP-1 medications following White House negotiations (November-December 2025) (www.fiercepharma.com)

5. Pennsylvania Health Law Project: Medicaid Coverage Changes – Documentation of Pennsylvania’s GLP-1 coverage criteria and announcement of coverage termination in January 2026 due to budget constraints (2024-2025) (www.phlp.org)

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499